Publication | Closed Access

Tumor-associated glycoantigen, sialyl Lewisa as a target for bispecific antibody-directed adoptive tumor immunotherapy

Tumor ImmunologyTumor-associated GlycoantigenMedicineImmunologyTumor ImmunityImmune Checkpoint InhibitorSialyl LewisaAntibody EngineeringImmunotherapeuticsTumor TargetingImmunotherapyOncologyRadiation OncologyTumor Microenvironment